ArticleWorld journal of gastroenterology2008
Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
Article in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Interventions for dialysis patients with hepatitis C virus (HCV) infection.The Cochrane database of systematic reviews · 2015Pooled it
- Interventions for dialysis patients with hepatitis C virus (HCV) infection.The Cochrane database of systematic reviews · 2023Review
- Treatment of hepatitis C in special populations.Journal of gastroenterology · 2018Review
- Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Journal of clinical and translational hepatology · 2016Review
- The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis.Hepatitis monthly · 2016Review
- Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.Journal of gastroenterology · 2016Observational
- Health care-associated hepatitis C virus infection.World journal of gastroenterology · 2014Review
- Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.International journal of nanomedicine · 2014Review
- Hepatitis C infection and chronic renal diseases.Hepatology international · 2013Article
- Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.Clinical and experimental nephrology · 2013Article
- Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.World journal of gastroenterology · 2012Article
- Hepatitis C and kidney transplantation.International journal of nephrology · 2011Article
- Hepatic disorders in chronic kidney disease.Nature reviews. Nephrology · 2010Review
- Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
methodsThirty-six hemodialysis patients with chronic hepatitis C were enrolled in a controlled and prospective study. All patients were treatment naive, positive tested for anti-HCV antibodies, and positive tested for serum HCV-RNA. Twenty-two patients received 135 microg peglyated-interferon alpha-2a weekly for 48 wk (group A). The remaining patients were left untreated, eleven refused therapy, and three were not candidates for kidney transplantation and were allocated to the control group (group B). At the end of the treatment biochemical and virological response was evaluated, and 24 wk after completion of therapy sustained virological response (SVR) was assessed. Side effects were monitored.
resultsOf 22 hemodialysis patients, 12 were male and 10 female, with a mean age of 35.2 +/- 12.1 years. Virological end-of-treatment response was observed in 14 patients (82.4%) in group A and in one patient (7.1%) in group B (P = 0.001). Sustained virological response was observed in 11 patients (64.7%) in group A and in one patient in group B (7.1%). Biochemical response parameters normalized in 10/14 patients (71.4%) at the end of the treatment. ALT levels in group B were initially high in six patients and normalized in one of them (25%) at the end of the 48 wk. In five patients (22.7%) therapy had to be stopped at mo 4 due to complications of weakness, anemia, and bleeding.
conclusionSVR could be achieved in 64.7% of patients on hemodialysis with chronic hepatitis C by a treatment with peglyated-interferon alpha-2a. Group A had a significantly better efficacy compared to the control group B, but the side effects need to be concerned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.